Kymera Therapeutics

Kymera Therapeutics company information, Employees & Contact Information

Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on delivering oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years.

Company Details

Employees
250
Founded
-
Address
500 North Beacon Street,
Email
in****@****atx.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Watertown, MA
Looking for a particular Kymera Therapeutics employee's phone or email?

Kymera Therapeutics Questions

News

Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025 - The Manila Times

Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025 The Manila Times

Discovery of KT-474─a Potent, Selective, and Orally Bioavailable IRAK4 Degrader for the Treatment of Autoimmune Diseases - ACS Publications

Discovery of KT-474─a Potent, Selective, and Orally Bioavailable IRAK4 Degrader for the Treatment of Autoimmune Diseases ACS Publications

Kymera Therapeutics (NASDAQ: KYMR) to report third quarter 2025; webcast at 8:30 a.m. ET - Stock Titan

Kymera Therapeutics (NASDAQ: KYMR) to report third quarter 2025; webcast at 8:30 a.m. ET Stock Titan

Clinical-Stage Biotech Kymera Therapeutics Set for 4 Major Investor Conferences Including Morgan Stanley - Stock Titan

Clinical-Stage Biotech Kymera Therapeutics Set for 4 Major Investor Conferences Including Morgan Stanley Stock Titan

Discovery of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates Targeting MYD88 Mutant Diffuse Large B-Cell Lymphoma - ACS Publications

Discovery of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates Targeting MYD88 Mutant Diffuse Large B-Cell Lymphoma ACS Publications

Markets - Medicine Hat News - FinancialContent

Markets - Medicine Hat News FinancialContent

Kymera Therapeutics to Report Second Quarter 2025 Financial Results on August 11, 2025 - The Manila Times

Kymera Therapeutics to Report Second Quarter 2025 Financial Results on August 11, 2025 The Manila Times

Top Kymera Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant